title: Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?
authors.affiliation: Section of Hematology, Department of Internal Medicine, Yale University and Yale Cancer Center, New Haven, Connecticut.
authors.forename: Maximilian
authors.initials: M
authors.lastname: Stahl
authors.affiliation: Section of Hematology, Department of Internal Medicine, Yale University and Yale Cancer Center, New Haven, Connecticut.
authors.forename: Amer M
authors.initials: AM
authors.lastname: Zeidan
mesh_terms: D001374:Azacitidine; D019175:DNA Methylation / Q000187:drug effects; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D009190:Myelodysplastic Syndromes
chemical_list: D056572:Histone Deacetylase Inhibitors; D001374:Azacitidine